Draft:Andre Rosowsky

• Comment: Please read carefully the guidelines for academics in WP:NPROF. While he has had a good career, there is nothing in this draft that meets those criteria. Does he have any major awards? Major interviews or other news items? Just publishing papers or being on grants/panels/editorial boards is not enough. Maybe you can focus on some of these and try again. Ldm1954 (talk) 14:20, 10 December 2023 (UTC)

---

Dr. Andre Rosowsky is a retired associate professor who spent more than 40 years as a research faculty member of the Dana-Farber Cancer Institute and Harvard Medical School, and simultaneously for a number of years as an adjunct faculty member at Northeastern University, all in Boston, Massachusetts.

Born in France in 1936, he came to the U.S. to live with an aunt and uncle in 1947 as the son of Nazi holocaust victims. He earned a B.S. degree in chemistry at the University of California (Berkeley) in 1957 and a Ph.D. in organic chemistry at the University of Rochester as an Abbott Fellow under the supervision of Professor D.S. Tarbell in 1961, then spent a year as National Science Foundation Fellow at Harvard University in the laboratory of Professor and eventual Nobel Prize winner E.J. Corey.

In addition to being the principal author or a co-author of more than 350 scientific articles , meeting abstracts, and book chapters, as well as being the principal inventor or co-inventor of more than twenty U.S and foreign patents , he is a former Editorial Board member of the Journal of Medicinal Chemistry and of the specialized international journal Pteridines, and was the editor of a volume in the celebrated multi-volume book series “Heterocyclic Compounds”. He also served for the maximum allowed time on three grant-review Study Sections (ET-1, ET-2, ARRD) of the National Institutes of Health (NIH), enabling laboratory and administrative support for numerous investigators in the cancer and AIDS fields.

He is chiefly known for the chemical synthesis and preclinical evaluation of novel dihydrofolate reductase (DHFR) inhibitors as potential anticancer and antiparasitic agents. One of these, originally code-named PT523 and later known as talotrexin, was patented and underwent a commercially sponsored and federally approved Phase 1 clinical trial in which favorable responses were observed in a number of patients . Before further commercial development had the opportunity to be carried out, he retired in 2008 at the age of seventy-two.